Cargando…

CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy

High-grade serous ovarian carcinoma (HGSC) is the most lethal gynecologic malignancy due to the lack of reliable biomarkers, effective treatment, and chemoresistance. Improving the diagnosis and the development of targeted therapies is still needed. The molecular pathomechanisms driving HGSC progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salgado-Albarrán, Marisol, Späth, Julian, González-Barrios, Rodrigo, Baumbach, Jan, Soto-Reyes, Ernesto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821627/ https://www.ncbi.nlm.nih.gov/pubmed/35132075 http://dx.doi.org/10.1038/s41540-022-00214-z

Ejemplares similares

The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer
por: Salgado-Albarrán, Marisol, et al.
Publicado: (2019)

Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection
por: Salgado-Albarrán, Marisol, et al.
Publicado: (2021)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

CTCF and Its Multi-Partner Network for Chromatin Regulation
por: Del Moral-Morales, Aylin, et al.
Publicado: (2023)

Genome-wide bioinformatics analysis reveals CTCFL is upregulated in high-grade epithelial ovarian cancer
por: Gong, Mi, et al.
Publicado: (2019)

The Evolution of Epigenetic Regulators CTCF and BORIS/CTCFL in Amniotes
por: Hore, Timothy A., et al.
Publicado: (2008)

Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells
por: Jones, Tania A., et al.
Publicado: (2011)

Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2011)

BORIS/CTCFL is an RNA-binding protein that associates with polysomes
por: Ogunkolade, Babatunji W, et al.
Publicado: (2013)

BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells
por: Renaud, Stéphanie, et al.
Publicado: (2011)

Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation
por: Nishana, Mayilaadumveettil, et al.
Publicado: (2020)

The Regulatory Roles of Non-coding RNAs in Angiogenesis and Neovascularization From an Epigenetic Perspective
por: Hernández-Romero, Itzel Alejandra, et al.
Publicado: (2019)

Transcriptomic and Drug Discovery Analyses Reveal Natural Compounds Targeting the KDM4 Subfamily as Promising Adjuvant Treatments in Cancer
por: del Moral-Morales, Aylin, et al.
Publicado: (2022)

CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity
por: Zambrano-Galván, Graciela, et al.
Publicado: (2014)

Choice of binding sites for CTCFL compared to CTCF is driven by chromatin and by sequence preference
por: Bergmaier, Philipp, et al.
Publicado: (2018)

Author Correction: Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation
por: Nishana, Mayilaadumveettil, et al.
Publicado: (2020)

The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
por: Dobbin, Zachary C., et al.
Publicado: (2013)

Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment
por: Wu, Yi-Hui, et al.
Publicado: (2020)

Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer
por: Malinowsky, K, et al.
Publicado: (2014)

BORIS (CTCFL) Is Not Expressed in Most Human Breast Cell Lines and High Grade Breast Carcinomas
por: Hines, William C., et al.
Publicado: (2010)

A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors
por: Loukinov, Dmitri, et al.
Publicado: (2023)

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
por: Sadegh, Sepideh, et al.
Publicado: (2020)

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
por: Cheaib, Bianca, et al.
Publicado: (2015)

PTPN18 Stimulates the Development of Ovarian Cancer by Activating the PI3K/AKT Signaling
por: Mao, Nan, et al.
Publicado: (2022)

Assembling pieces of the centromere epigenetics puzzle
por: González-Barrios, Rodrigo, et al.
Publicado: (2012)

Early vertebrate origin of CTCFL, a CTCF paralog, revealed by proximity-guided shark genome scaffolding
por: Kadota, Mitsutaka, et al.
Publicado: (2020)

BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells
por: Janssen, Sanne Marlijn, et al.
Publicado: (2020)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
por: Aziz, Aziz Ur Rehman, et al.
Publicado: (2018)

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
por: Gasparri, Maria Luisa, et al.
Publicado: (2017)

Targeting the PI3K/AKT/mTOR/NFκB Axis in Ovarian Cancer
por: Ghoneum, Alia, et al.
Publicado: (2020)

Retracted: PTPN18 Stimulates the Development of Ovarian Cancer by Activating the PI3K/AKT Signaling
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies
por: Voutsadakis, Ioannis A.
Publicado: (2018)

Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2
por: Yao, Haibo, et al.
Publicado: (2021)

Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma
por: De Marco, Carmela, et al.
Publicado: (2013)

Lanthanum Chloride Sensitizes Cisplatin Resistance of Ovarian Cancer Cells via PI3K/Akt Pathway
por: Fang, Shanyu, et al.
Publicado: (2021)

DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway
por: Li, Meng, et al.
Publicado: (2022)

Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis
por: Driva, Tatiana S., et al.
Publicado: (2023)

Getting the Akt Together: Guiding Intracellular Akt Activity by PI3K
por: Yudushkin, Ivan
Publicado: (2019)

HijAkt: The PI3K/Akt Pathway in Virus Replication and Pathogenesis
por: Dunn, Ewan F., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sp9r5cj8hlrsqk02lb5336ceni